TAG Mail 3 May 2017

The purpose of TAGMail is to assist TAG members identify and share relevant information for their professional practice. Members are encouraged to routinely forward TAGMail to others who they believe would benefit from this information such as colleagues in the same hospital department if they are not already receiving TAGMail. NSW TAG may be contacted via email nswtag@stvincents.com.au or by calling 02 8382 2852.

TAG ACTIVITIES

**Upcoming Meetings**
TAG General Committee meeting: 15th May 2017
TAGNet meeting: 16th May 2017

CONSULTATIONS

- Consultation: Options for the future regulation of ‘low risk’ products. Closes 12 May 2017

REPORTS AND PUBLICATIONS – AUSTRALIA

**CEC**
- Paediatric Watch Edition 2/17 ‘Falls: Keep them safe’

**TGA**
- Recall: Hyland’s Baby homeopathic teething tablets
- AusPAR added: Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (as sodium salt) and Ribavirin (Viekira Pak-RBV™) for the treatment of genotype 1 chronic hepatitis infection, including patients with compensated cirrhosis.
- Updates to the list of designated orphan drugs:
  Dexamethasone Intravitreal Implant (Ozurdex™) for the treatment of non-infections uveitis affecting the posterior section of the eye
  Obeticholic acid for the treatment of primary biliary cholangitis (PBC)

REPORTS AND PUBLICATIONS – INTERNATIONAL

**AHRQ Patient Safety Network**
- Translating concerns into action: a detailed qualitative evaluation of an interdisciplinary intervention on medical wards
  http://bmjopen.bmj.com/content/7/4/e014401
- Assessing the Impact of the Anesthesia Medication Template on Medication Errors During Anesthesia: A Prospective Study

**EMA**
- EMA and heads of national competent authorities discuss consequences of Brexit
**FDA**
- Regorafenib (Stivarga™) now approved to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555608.htm](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555608.htm)
- Cerliponase alfa (Brineura™) approved as a treatment for a specific form of Batten disease. [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555613.htm](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555613.htm)
- Midostaurin (Rydapt™) approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm)

*HCO NZ*

**NICE**
- Daclizumab for treating relapsing–remitting multiple sclerosis [https://www.nice.org.uk/guidance/ta441/](https://www.nice.org.uk/guidance/ta441/)
- Ixekizumab for treating moderate to severe plaque psoriasis [https://www.nice.org.uk/guidance/ta442/](https://www.nice.org.uk/guidance/ta442/)
- Obeticholic acid for treating primary biliary cholangitis [https://www.nice.org.uk/guidance/ta443/](https://www.nice.org.uk/guidance/ta443/)

**Specialist Pharmacy Service**

**MEDICATION SAFETY**

**CADTH**
Cannabis Use During Pregnancy: Safety [https://www.cadth.ca/cannabis-use-during-pregnancy-safety-0](https://www.cadth.ca/cannabis-use-during-pregnancy-safety-0)

**FDA**

**TGA**
OTHER NEWS
**ISMP International Safe Medication Management Fellowship
This new 2-year Fellowship will help train medication safety leaders capable of creating change on a global level. **Application deadline: June 30, 2017**

PAPERS OF INTEREST
**AJHP
- Minimization of olaratumab drug waste using real-world data
http://www.ajhp.org/content/early/2017/04/25/ajhp160254?papetoc=

**Annals of Oncology
- Do patient access schemes for high-cost cancer drugs deliver value to society? Lessons from the NHS Cancer Drugs Fund

**British Journal of Clinical Pharmacology
- Risk factors of adverse health outcomes after hospital discharge modifiable by clinical pharmacist interventions - a review with a systematic approach

**BMJ
- Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
http://www.bmj.com/content/357/bmj.i1550
- Evolution of biological agents: how established drugs can become less safe
http://www.bmj.com/content/357/bmj.i1707

**European Heart Journal
- Alcohol consumption, sinus tachycardia, and cardiac arrhythmias at the Munich Octoberfest: results from the Munich Beer Related Electrocardiogram Workup Study (MunichBREW)
https://academic.oup.com/eurheartj/article/3748448/Alcohol-consumption-sinus-tachycardia-and-cardiac

**Internal Medicine Journal
- Approaches for Optimising Intravenous Iron Dosing in Pregnancy: A Retrospective Cohort Study
- Antenatal maternal Hepatitis B care is a predictor of timely perinatal administration of Hepatitis B immunoglobulin

**JAMA Internal Medicine
- Behavioral Approach to Appropriate Antimicrobial Prescribing in Hospitals: The Dutch Unique Method for Antimicrobial Stewardship (DUMAS) Participatory Intervention Study
http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2623529

**Journal of Clinical Oncology
- Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update

**NEJM
- Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
- Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
**The Lancet**
- Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

**The Lancet – Diabetes and Endocrinology**
- Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial

**UPCOMING EVENTS (new additions in bold)**

**HISA NSW – Health innovation – considering digital tipping points and ‘what works’**
May 11th 2017, 6:00 pm - 8:00 pm, Macquarie Health

**CEC Medical Leadership Forum**
12th May 2017, 9-5pm, Cliftons Conference Centre, 60 Margaret Street Sydney

**6th Biennial Update in Paediatric Respiratory Medicine, 12th May 2017, Sydney Children’s Hospital Randwick**

**Cerner Australia, ‘Regional User Group Australia 2017’, 17-19th May 2017, Sofitel Central Brisbane.**
[https://www.ivvy.com/event/RUG17/](https://www.ivvy.com/event/RUG17/)

**1st Australasian Diagnostic Error in Medicine Conference, Melbourne, 24-25 May 2017**
[www.improvediagnosis.org/AusDEM17](http://www.improvediagnosis.org/AusDEM17)

**NSW Agency for Clinical Innovation - Shared Decision Making Masterclass: Making Health Decisions Together, 26th May 2017, Sydney**

**Vivid Sydney ‘Dare to Design Our Healthcare Future – Reimagining the Future of Australia’s Healthcare Future’ 2nd June, 9 Barnett Long Room, Customs House, 31 Alfred Street Sydney**
[https://www.vividsydney.com/event/ideas/dare-design-our-health-future](https://www.vividsydney.com/event/ideas/dare-design-our-health-future)

**Women and Heart Disease Forum, 14th June 2017, Qantas Centre of Service Excellence, 70-80 Euston Road, Alexandria NSW**

**Division of Pharmacoepidemiology and Clinical Pharmacology International Summer Courses**
Utrecht University, The Netherlands
3-7 July 2017 - Pharmacoepidemiology & Drug safety
10-14 July 2017 - Pharmaceutical Policy Analysis (WHO CC for Pharmaceutical Policy and Regulation)
17-21 July 2017 - Pharmacoeconomics
More detailed information can be found below or on the summer school website ([http://www.utrechtsummerschool.nl](http://www.utrechtsummerschool.nl)).

**Healthcare Leaders Forum, Swissotel, Sydney, 22 & 23 August 2017**

**6th World Congress of Clinical Safety 2017, Roma, Italy, 6-8th September 2017**
Abstract submission to 31 March 2017
[http://www.iarmm.org/6WCCS/](http://www.iarmm.org/6WCCS/)
**ISQua’s 34th International Conference**
‘Learning at the System Level to Improve Healthcare Quality and Safety’ 1-4 October 2017, London

**CEC’s ‘Advanced Measurement and Variation Workshop’ 23rd October (additional workshop on 13th November)**

You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at [nswtag@stvincents.com.au](mailto:nswtag@stvincents.com.au) if you have any questions regarding this.